M. Tsujimoto

发表

Comparison of Two Ethnic Populations Using Distribution Adjusted Mean

Zhihong Cai, H. Uesaka, M. Tsujimoto, 2013, Journal of biopharmaceutical statistics.

PINP as an aid for monitoring patients treated with teriparatide.

J. Krege, H. Sowa, Peiqi Chen, 2011, Bone.

Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis

Toshitaka Nakamura, H. Sowa, Peiqi Chen, 2012, Journal of Bone and Mineral Metabolism.

Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases.

Toshitaka Nakamura, Toshio Matsumoto, M. Warner, 2010, Bone.

Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS)

S. Fujiwara, M. Tsujimoto, Masayo Sato, 2018, Archives of Osteoporosis.

Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis

H. Sowa, M. Tsujimoto, Takanori Yamamoto, 2013, Journal of Bone and Mineral Metabolism.

Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation

H. Sowa, M. Tsujimoto, Takanori Yamamoto, 2015, Clinical interventions in aging.

Clinical Interventions in Aging Dovepress

H. Sowa, M. Tsujimoto, Takanori Yamamoto, 2022 .

Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study

T. Satoh, Y. Omuro, T. Nishina, 2018, Gastric Cancer.

Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy

H. Sowa, M. Tsujimoto, K. Uenaka, 2012, Journal of Bone and Mineral Metabolism.

Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study

Toshitaka Nakamura, Toshio Matsumoto, D. Thiebaud, 2008, Journal of Bone and Mineral Metabolism.

Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS)

R. Takayanagi, J. Krege, S. Fujiwara, 2017, Current medical research and opinion.

Japan Fracture Observational Study (JFOS): patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis

R. Takayanagi, J. Krege, S. Fujiwara, 2015, Current medical research and opinion.